Answers are grounded in this paper and cite their sources.
Demonstrates the potential of novel alkaloids to enhance the effects of cisplatin in ovarian cancer cells, suggesting new therapeutic strategies.
Four novel monoterpene indole alkaloids, designated rauvolvomines A–D ( 1 – 4 ), were isolated from Rauvolfia vomitoria and characterized as potent platinum-based sensitizers possessing unusually diverse carbon skeletons. Their structures were elucidated through comprehensive spectroscopic analysis, single-crystal X-ray diffraction, and ECD calculations. Rauvolvomines A ( 1 ) and B ( 2 ) shared a novel 6/5/5/6/6 pentacyclic scaffold featuring a caged 7-aza-tricyclo[4.3.1.0 3,8 ]decane core fused to an indole moiety. Rauvolvomine C ( 3 ) possessed an unprecedented 6/5/5/5/6/6 hexacyclic skeleton incorporating an extra furan ring, based on the rare class of sarpagine-oxide alkaloids characterized by a 5′ H -spiro[indoline-3,1′-[3,7]methanoindolizin]-2-one core. Rauvolvomine D ( 4 ) represented the first example of a rearranged 18(19→21)- abeo sarpagine-oxide alkaloid. Plausible biosynthetic pathways were proposed. Biologically, skeletons 1 and 3 demonstrated strong synergy with cisplatin across SKOV3 and OVCAR3 cell lines (CI < 0.6), while 2 and 4 enhanced cisplatin sensitivity specifically in SKOV3 cells. Skeletons 1 and 3 were particularly effective in potentiating cisplatin’s cytotoxicity, leading to a significant 1.48- to 5.14-fold reduction in its IC 50 values by potently inducing S-phase arrest and promoting apoptosis. These findings highlighted novel skeletons 1 and 3 as promising molecular scaffolds for development as cisplatin sensitizers in the treatment of ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: